From: Morbidity and mortality of nonagenarians undergoing CoreValve implantation
Variable | |
---|---|
Clinical parameters | |
Male, n (%) | 4 (36.4) |
Age (yrs) | 92.6 ± 1.3 |
BMI (kg/m2) | 28.6 ± 3.0 |
Hypertension, n (%) | 9 (81.8) |
Dyslipidemia (%) | 9 (81.8) |
Smoker, n (%) | 3 (27.3) |
Diabetes mellitus, n (%) | 7 (63.6) |
Renal insufficiency (creatinine level > 1.5mg/dl), n (%) | 6 (54.5) |
Chronic hemodyalisis, n (%) | 2 (18.2) |
Chronic obstructive pulmonary disease, n (%) | 2 (18.2) |
New York Heart Association functional class (grade) | 3.2 ± 0.8 |
Logistic EuroSCORE (%) | 32.0 ± 9.5 |
STS score (%) | 25.3 ± 9.7 |
Dyspnoe, n (%) | 11 (100) |
Angina, n (%) | 4 (36.4) |
Syncope, n (%) | 4 (36.4) |
Cardiac decompensation, n (%) | 5 (45.5) |
Pulmonal artery systolic pressure (mmHg) | 40.8 ± 18.7 |
Porcelain aorta, n (%) | 0 (0) |
Ischemic heart disease, n (%) | 8 (72.7) |
Previous percutaneous coronary intervention, n (%) | 6 (54.5) |
Previous coronary artery bypass graft surgery, n (%) | 4 (36.4) |
Peripheral vessel disease, n (%) | 2 (18.2) |
Previous stroke, n (%) | 2 (18.2) |
Laboratory findings | |
Hemoglobin (mg/dl) | 7.8 ± 1.2 |
Hematokrit (%) | 37.7 ± 4.8 |
Creatinine (μmol/l) | 183.9 ± 223.6 |
MDRD | 48.2 ± 24.6 |
Medication | |
Aspirin | 7 (63.6) |
ACE-Inhibitor | 7 (63.6) |
ARB | 2 (18.2) |
Beta-Blocking agent | 8 (72.7) |
Ca-chanel blocker | 3 (27.3) |
Antiarythmic agent | 0 (0) |
Statin | 7 (63.6) |